I am glad you reached this page

I am genuinely happy to respond to questions about how pharmaceutical royalty streams are structured, what the due diligence process typically involves, and how the content on this site is organized. Those conversations are exactly what this resource exists to support. What I cannot do — and will always say plainly — is provide personalized financial advice, assess whether a specific arrangement suits your individual circumstances, or offer anything that substitutes for the counsel of a registered Canadian financial advisor or securities lawyer. If your question takes you in that direction, I will tell you so honestly and point you toward the appropriate professional. That is not a limitation I apologize for; it is a boundary I hold because it is genuinely in your interest.